Skip to main content

Table 2 Non-recurrent vs. recurrent group

From: Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy

 

All patients

Non-recurrent

Recurrent

p value

Age (n)

32

23

9

 

 Median, IQR

83, 79–85

83, 79–85

82, 81–85

0.916

Gender

 Female

13

9

4

1.000

 Male

19

14

5

 

Histology

 Ad

24

18

6

0.655

 Non-Ad

8

5

3

 

Morphology

 Solid/part solid

26

17

9

0.150

 GGO

6

6

0

 

Dose

 40 Gy (PTV D95)

23

17

6

0.685

 48 Gy (isocenter)

9

6

3

 

Tumor diameter

23.0, 17.0–32.3

21.0, 15.0–27.5

28.0, 26.0–35.0

0.013

FDG SUVmax

7.89, 2.00–10.1

6.02, 1.81–8.94

9.73, 8.46–13.2

0.005

FDG MTV

6.62, 1.15–10.0

6.21, 3.71–9.50

8.19, 3.52–10.8

0.586

FMISO SUVmax

1.50, 0.88–2.05

1.15, 0.82–1.59

2.21, 1.90–2.74

< 0.001

FMISO TMR

1.11, 0.72–1.80

0.83, 0.68–1.19

2.22, 1.79–2.44

< 0.001

FMISO TBR

0.91, 0.63–1.41

0.75, 0.60–1.04

1.70, 1.37–1.80

< 0.001

  1. FDG fluorodeoxyglucose, FMISO fluoromisonidazole, IQR interquartile range, MTV metabolic tumor volume, PTV planning target volume, SUVmax maximum of standardized uptake value, TBR tumor-to-blood ratio, TMR tumor-to-muscle ratio